Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

The Tracking Resistance to Artemisinin Collaboration II (TRACII) study has begun recruitment, with about 180 subjects enrolled to date in 12 sites in seven countries in Asia and Africa, researchers announced at the second TRACII investigators’ meeting held 7 March in Bangkok.

Scientist operating a microscope

17 March 2016, Bangkok – The Tracking Resistance to Artemisinin Collaboration II (TRACII) study has begun recruitment, with about 180 subjects enrolled to date in 12 sites in seven countries in Asia and Africa, researchers announced at the second TRACII investigators’ meeting held 7 March in Bangkok.

In 2014, the first TRAC study confirmed that resistance of falciparum malaria to the world’s most effective antimalarial drug, artemisinin, was widespread in Southeast Asia. Health experts fear that artemisinin resistant parasites will spread from their original Cambodian-Thai border epicentre in Southeast Asia and emerge on the Indian subcontinent and then sub-Saharan Africa, putting millions of lives at risk.

Coordinated by the Mahidol Oxford Tropical Medicine Research Unit (MORU) the TRACII study investigates the efficacy, safety and tolerability of triple artemisinin combination therapies (TACTs), which consist of a rapidly acting artemisinin derivative in combination with two slowly eliminated antimalarial partner drugs.

“Falciparum malaria is becoming almost untreatable in the region and new antimalarials are years away. TACTs combining existing antimalarial drugs may prove to be our most important remaining treatment option,” said Prof. Arjen Dondorp, Head of Malaria at MORU and principal investigator of TRACII, at the meeting.

Artemisinin resistance selects for resistance toward the partner drug, causing alarmingly low cure rates with artemisinin-based combination therapies (ACTs) in several countries of the Greater Mekong Sub-region. Deploying TACTs, which combine three drugs rather than two drugs as in conventional ACTs, might be an important treatment solution. 

“The TACTs that are currently assessed in TRACII are a combination of DHA-piperaquine plus mefloquine in Cambodia, Vietnam, Thailand and Myanmar and a combination of artemether-lumefantrine plus amodiaquine in Laos, Myanmar, Bangladesh, India and the Democratic Republic of the Congo. In total the TRACII project will enrol 2,040 subjects in 17 study sites in these eight countries,” said Dr Rob van der Pluijm, TRACII project coordinator.

In addition to discussions on the core study, TRAC II collaborators from the London School of Hygiene and Tropical Medicine (LSHTM), Institut Pasteur and the Armed Forces Research Institute of Medical Science (AFRIMS) presented preliminary results and future plans for their own TRACII related projects at the annual meeting.

“The TRAC studies are possible thanks to contributions from many regional and international partners,” said Dr Mehul Dhorda, head of the Asia Regional Centre & EQA Programme, WorldWide Antimalarial Resistance Network (WWARN). “The harmonised protocols and procedures being used for these studies will allow us to track resistance and directly compare data generated over time in disparate locations across the Greater Mekong Subregion.”

TRACII is funded by the United Kingdom Department for International Development (DFID).

Similar stories

Patient recruitment on track in Oxford-led DeTACT trial of safe, effective drug combinations to prevent the spread of artemisinin and multi-drug resistant malaria in Africa

Today is World Malaria Day. The global fight against malaria is at a critical point. No new antimalarial drugs are expected in the near future, and if multi-drug resistant falciparum malaria becomes established in East Africa and spreads to other parts of Africa, millions will be at risk of drug-resistant malaria infection and death. The development of triple artemisinin-based combination therapies aims to prevent or delay the emergence of artemisinin and multi-drug resistant malaria in Africa.

TACT-CV study shows artemether–lumefantrine plus amodiaquine an effective treatment for multidrug-resistant malaria in GMS

A triple artemisinin-based combination therapy (TACT) of artemether-lumefantrine plus amodiaquine (AL+AQ) for uncomplicated falciparum malaria in areas with a high prevalence of artemisinin resistance is a well-tolerated, effective treatment for multidrug-resistant parasites, say a team of MORU-led researchers.

Largest-ever IPD meta-analysis of malaria patients to inform haemoglobin changes

A new malaria study using a very large analysis of pooled individual patient data (IPD) from more than 70,000 patients of all ages, has been published in BMC Medicine by the WorldWide Antimalarial Resistance Network Falciparum Haematology Study Group

Study finds steady increase in WHO-validated artemisinin resistance markers in Asia

From 2002-2018, there has been a steady increase in the places and proportion of infected people reporting validated kelch13 (K13) artemisinin resistance markers, according to a study in The Lancet Microbe. This increase in artemisinin resistance threatens efforts to eliminate malaria in Asia by 2030 — and control efforts in other endemic regions. The authors say that more consistent data collection, over longer time periods in the same areas, and rapid sharing of data are needed to map the spread of resistance and better inform policy decisions.

Global Research on AntiMicrobial resistance (GRAM) project

Antimicrobial resistance (AMR) is responsible for at least 1.27 million deaths per year — with over 97,000 deaths in 2019 in SE Asia alone, according to a study published in The Lancet by the Global Research on AntiMicrobial resistance (GRAM) project, who urged urgent action from policymakers and health communities to avoid further preventable deaths.

Susie, Phaik Yeong, Richard and Paul among new full Oxford professors!

In the 2021 Oxford Recognition of Distinction round, four MORU colleagues were awarded Full Professor title.